Group 1 - The company expects a loss attributable to shareholders of approximately HKD 150 million for the six months ending June 30, 2025, an improvement compared to a loss of approximately HKD 240 million for the same period in 2024 [1] - The reduction in loss is primarily due to an expected investment portfolio income of approximately HKD 219.8 million for the six months ending June 30, 2025, compared to HKD 127.8 million for the same period in 2024 [1][2] - The company anticipates a net loss from the valuation of investment properties of approximately HKD 471 million for the six months ending June 30, 2025, compared to a loss of HKD 516 million for the same period in 2024 [1] Group 2 - Excluding the net loss from investment property valuations and related deferred tax items, the company expects a basic profit attributable to shareholders to increase by approximately 27.1% to about HKD 321 million for the six months ending June 30, 2025, compared to HKD 253 million for the same period in 2024 [1] - The company projects a decrease in investment property income of approximately 17.1% to about HKD 160 million for the six months ending June 30, 2025, down from HKD 193.4 million for the same period in 2024, mainly due to weak demand for office space leading to lower rents and occupancy rates [2] - The department store business is expected to incur a loss of approximately HKD 38.5 million for the six months ending June 30, 2025, compared to a loss of HKD 27 million for the same period in 2024, primarily due to changes in consumer behavior among Hong Kong residents and increased overseas travel and cross-border shopping [2]

Group 1 - The company expects a loss attributable to shareholders of approximately HKD 150 million for the six months ending June 30, 2025, an improvement from a loss of approximately HKD 240 million for the same period in 2024 [1] - The reduction in loss is primarily due to an expected investment portfolio income of approximately HKD 219.8 million for the six months ending June 30, 2025, compared to HKD 127.8 million for the same period in 2024 [1] - The company anticipates a net loss from property valuation of approximately HKD 471 million for the six months ending June 30, 2025, compared to a loss of HKD 516 million for the same period in 2024 [1] Group 2 - The company projects a basic profit attributable to shareholders to increase by approximately 27.1% to about HKD 321 million for the six months ending June 30, 2025, compared to HKD 253 million for the same period in 2024 [1] - The expected investment portfolio income is mainly derived from the revaluation of securities held for trading and gains from the sale of these securities [1] - The company anticipates a decrease in investment property income of approximately 17.1% to about HKD 160 million for the six months ending June 30, 2025, down from HKD 193.4 million for the same period in 2024, due to weak demand for office space [2] Group 3 - The company expects a loss of approximately HKD 38.5 million from its department store business for the six months ending June 30, 2025, compared to a loss of HKD 27 million for the same period in 2024 [2] - The increase in department store losses is attributed to changes in consumer behavior among Hong Kong residents, as well as increased overseas travel and cross-border shopping [2]

Core Viewpoint - WING ON CO (00289.HK) anticipates a loss attributable to shareholders of approximately HKD 150.4 million for the six months ending June 30, 2025, an improvement compared to a loss of HKD 239.6 million for the same period ending June 30, 2024 [1] Financial Performance - The company expects a basic profit attributable to shareholders to increase by approximately 27.1% to about HKD 321.1 million for the six months ending June 30, 2025, compared to a basic profit of HKD 252.6 million for the six months ending June 30, 2024 [1]

(百慕達註冊成立有限公司) (股份代號︰289) 盈利預告 - 虧損減少 截至 2025 年 6 月 30 日止 6 個月 本公告乃本公司根據上市規則第 13.09(2) 條及證券及期貨條例（香港法例第 571 章） 第 XIVA 部項下之內幕消息條文作出。 董事會謹此知會股東及潛在投資者，根據管理層目前掌握截至 2025 年 6 月 30 日止 6 個月未經審核之綜合管理賬目所作的初步審閱，本集團預期截至 2025 年 6 月 30 日止 6 個月將錄得應撥歸股東虧損約為 150.4 百萬港元，相對比截至 2024 年 6 月 30 日止 6 個月則為虧損 239.6 百萬港元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 WING ON COMPANY INTERNATIONAL LIMITED 永安國際有限公司 截至 2025 年 6 月 30 日止 6 個月，本集團於香港及澳洲墨爾本的投資物業收入預期減少約 17.1% 至約 160.3 ...

Core Viewpoint - Lidman plans to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the company and enhance its IVD business segment, particularly in tuberculosis diagnosis and treatment [1][2]. Group 1: Transaction Details - The acquisition involves a cash purchase of shares from shareholders of Xiansheng Xiangrui, with no prior ownership of the target company by Lidman [1]. - The transaction is expected to constitute a major asset restructuring, and Lidman's stock will not be suspended during this process [1][2]. - The funding for the acquisition will come from Lidman's own funds and bank acquisition loans, with the transaction price yet to be determined [2]. Group 2: Company and Industry Insights - Xiansheng Xiangrui operates in the biopharmaceutical manufacturing industry, focusing on in vivo diagnostic reagents and human vaccines, particularly for tuberculosis screening and treatment [1]. - Lidman is one of the earliest companies in China engaged in the research, production, and sales of biochemical diagnostic reagents [2]. - The acquisition is expected to enhance Lidman's competitive edge by adding tuberculosis diagnosis and treatment capabilities, aligning with the interests of the company and its shareholders [2]. Group 3: Market Performance - Lidman's stock has seen a significant increase, with a cumulative rise of over 44% from April 8 to the present, reaching a closing price of 5.87 yuan per share and a total market capitalization of 3.2 billion yuan [3].

Group 1 - The core point of the article is that Lidman is planning to acquire up to 70% of the shares of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. in cash, which will give Lidman control over Xiansheng Xiangrui, making it a subsidiary [1][3] - The acquisition is expected to constitute a major asset restructuring, and Lidman's stock will not be suspended during this process [1][3] - The target company operates in the biopharmaceutical manufacturing industry, focusing on in vitro diagnostic reagents and human vaccines, with key products related to tuberculosis screening and treatment [3] Group 2 - The funding for the acquisition will come from Lidman's own funds combined with bank acquisition loans, although the transaction price has not yet been determined [3] - The rationale behind the acquisition is to enhance Lidman's IVD business by adding tuberculosis diagnostic and treatment capabilities, which aligns with the company's strategic goals [4] - Lidman is one of the earliest companies in China engaged in the research, production, and sales of biochemical diagnostic reagents [5]

Group 1 - Lideman is planning a major asset restructuring by acquiring up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. This acquisition will grant Lideman control over the target company, which will become a subsidiary [1][2] - The target company specializes in in vitro diagnostic reagents and human vaccines, with products primarily used for tuberculosis screening, diagnosis, treatment, and innovative vaccine development. The acquisition will enhance Lideman's IVD business segment and overall competitiveness [2] Group 2 - Hehua Co. and Sanchao New Materials are planning control changes, leading to a suspension of their stocks starting July 31, 2025, for up to two trading days [3] - Changjiang Electric Power has approved an investment of approximately 26.6 billion yuan for the construction of the Gezhouba shipping capacity expansion project, with funding sourced from its own funds [4] Group 3 - Contemporary Amperex Technology Co., Ltd. (CATL) reported a 7.27% increase in revenue to 178.886 billion yuan and a 33.33% increase in net profit to 30.485 billion yuan for the first half of 2025. The company plans to distribute a cash dividend of 10.07 yuan per 10 shares [5] - Dingtong Technology reported a 73.51% increase in revenue to 0.785 billion yuan and a 134.06% increase in net profit to 0.115 billion yuan for the first half of 2025 [6] - XGIMI Technology expects a net profit of 88.662 million yuan for the first half of 2025, a significant increase of 2062.33% compared to the previous year [7] Group 4 - Jinchengzi is planning to acquire 55% of Changchun Samit Optoelectronics Technology Co., Ltd. through a combination of stock issuance and cash payment, with the stock suspension starting July 31, 2025, for up to 10 trading days [8] - Digital Certification is undergoing a change in its controlling shareholder due to the establishment of Beijing Data Group, which will involve the transfer of shares from its current controlling shareholder [9][10]

Core Viewpoint - Lidman is planning to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which is expected to constitute a major asset restructuring [1][4]. Group 1: Acquisition Details - The acquisition will be funded through self-owned funds and bank merger loans, with Lidman not holding any shares in the target company prior to the transaction [4]. - Upon completion of the acquisition, Lidman will gain control of the target company, which will become a subsidiary [4]. - The investment framework agreement signed with the target company and its shareholders is only a preliminary agreement, with specific terms to be defined in formal agreements [4]. Group 2: Target Company Overview - The target company operates in the biopharmaceutical manufacturing industry, focusing on in vitro diagnostic reagents and human vaccines [4]. - Its main products include tuberculin purified protein derivative, bacillus Calmette-Guérin purified protein derivative, and specific cell immune response test kits for tuberculosis screening, diagnosis, treatment, and innovative vaccine development [4]. Group 3: Financial Performance - In 2024, Lidman reported a revenue of approximately 370 million yuan, a year-on-year decrease of 19.79%, with a net profit of -75.1 million yuan [6]. - The in vitro diagnostic reagent business remains the primary revenue source, generating about 297 million yuan, down 22.06%, accounting for 80.29% of total revenue [6]. - The first quarter of 2025 saw revenues of approximately 78.9 million yuan, a year-on-year decline of 16.61%, with a net profit of -1.25 million yuan [6]. Group 4: Market Position - As of July 30, Lidman's stock price was 5.87 yuan per share, with a market capitalization of 3.2 billion yuan [7].

Group 1 - Heartway Medical-B (06609.HK) expects a net profit of no less than RMB 40 million for the six months ending June 30, 2025, a significant turnaround from a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] - The anticipated profit and performance improvement are primarily due to business growth, leading to increased revenue and a decrease in overall expenditure ratio compared to the corresponding period [1] Group 2 - Baoshan International (03813.HK) expects a mid-term net profit of approximately RMB 187.6 million, a year-on-year decrease of 44.1% [2] - Baio Family Interaction (02100.HK) anticipates a mid-term profit increase of approximately 134.9% to 141.6% [2] - Skyworth Group (00751.HK) warns of an expected mid-term post-tax profit decline of about 50% year-on-year [2] Group 3 - China CNR Corporation (01766.HK) recently signed a significant contract worth approximately RMB 32.92 billion [2] - China Power (02380.HK) reported a total electricity sales volume of 11.299 million megawatt-hours in June, a year-on-year decrease of 5.04% [2]

智通财经APP讯，WING ON CO(00289)发布公告，于2025年7月29日注销合共9.4万股已购回股份。 ...